Tokyo Tape
Sign in
← Soiken Holdings

Quarterly report · Q2

2385.TEDINET S100SUZ2
Period2023-07-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥2.8bn2023-07-01 → 2023-12-31Cons.Net sales
Revenue¥8.1bn2022-07-01 → 2023-06-30Cons.Net sales (5-year summary)
Revenue¥4.2bn2022-07-01 → 2022-12-31Cons.Net sales
Operating income−¥455m2023-07-01 → 2023-12-31Cons.Operating income
Operating income¥345m2022-07-01 → 2022-12-31Cons.Operating income
Ordinary income−¥449m2023-07-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥727m2022-07-01 → 2023-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥345m2022-07-01 → 2022-12-31Cons.Ordinary income
Profit before tax−¥449m2023-07-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥345m2022-07-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)−¥488m2023-07-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥452m2022-07-01 → 2023-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥209m2022-07-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income−¥489m2023-07-01 → 2023-12-31Cons.Profit loss
Net income¥213m2022-07-01 → 2022-12-31Cons.Profit loss
Total assets¥7.1bnat 2023-12-31Cons.Assets
Total assets¥8.2bnat 2023-06-30Cons.Assets
Total assets¥8.0bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥702mat 2023-12-31Cons.Liabilities
Total liabilities¥1.1bnat 2023-06-30Cons.Liabilities
Net assets / equity¥6.4bnat 2023-12-31Cons.Net assets
Net assets / equity¥7.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥6.9bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥4.7bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥5.9bnat 2023-06-30Cons.Cash and deposits
Cash & equivalents¥4.7bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥5.9bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.5bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥6.0bnat 2022-06-30dCons.Cash and cash equivalents
Operating cash flow−¥967m2023-07-01 → 2023-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥102m2022-07-01 → 2023-06-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥328m2022-07-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥10m2023-07-01 → 2023-12-31Cons.Net cash provided by used in investment activities
Investing cash flow¥160m2022-07-01 → 2023-06-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥27m2022-07-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥260m2023-07-01 → 2023-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥130m2022-07-01 → 2023-06-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥130m2022-07-01 → 2022-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥-18.652023-07-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥1.52023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.272022-07-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥82022-07-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥7.472022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio89.9%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio84.6%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio84.4%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 49
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-12-31−¥10m
Reconciling Itemsreconcilingrevenue external2023-07-01 → 2023-12-31¥900,000
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-12-31−¥11m
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-12-31−¥156m
jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segmentrevenue2023-07-01 → 2023-12-31¥176m
jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segmentrevenue external2023-07-01 → 2023-12-31¥176m
jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segmentsegment profit2023-07-01 → 2023-12-31¥1m
jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segmentrevenue2023-07-01 → 2023-12-31¥779m
jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segmentrevenue external2023-07-01 → 2023-12-31¥779m
jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segmentsegment profit2023-07-01 → 2023-12-31−¥72m
jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segmentrevenue2023-07-01 → 2023-12-31¥1.4bn
jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segmentrevenue external2023-07-01 → 2023-12-31¥1.4bn
jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segmentrevenue intersegment2023-07-01 → 2023-12-31¥3m
jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segmentsegment profit2023-07-01 → 2023-12-31−¥270m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentrevenue2023-07-01 → 2023-12-31¥165m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentrevenue external2023-07-01 → 2023-12-31¥157m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentrevenue intersegment2023-07-01 → 2023-12-31¥8m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentsegment profit2023-07-01 → 2023-12-31−¥701,000
jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segmentrevenue2023-07-01 → 2023-12-31¥337m
jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segmentrevenue external2023-07-01 → 2023-12-31¥337m
jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segmentsegment profit2023-07-01 → 2023-12-31¥43m
—segment totalrevenue2023-07-01 → 2023-12-31¥2.9bn
—segment totalrevenue external2023-07-01 → 2023-12-31¥2.8bn
—segment totalrevenue intersegment2023-07-01 → 2023-12-31¥11m
—segment totalsegment profit2023-07-01 → 2023-12-31−¥299m
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-12-31−¥2m
Reconciling Itemsreconcilingrevenue external2022-07-01 → 2022-12-31¥900,000
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-12-31−¥3m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-12-31−¥155m
jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segmentrevenue2022-07-01 → 2022-12-31¥258m
jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segmentrevenue external2022-07-01 → 2022-12-31¥258m
jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segmentsegment profit2022-07-01 → 2022-12-31¥32m
jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segmentrevenue2022-07-01 → 2022-12-31¥2.0bn
jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segmentrevenue external2022-07-01 → 2022-12-31¥2.0bn
jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segmentsegment profit2022-07-01 → 2022-12-31¥398m
jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segmentrevenue2022-07-01 → 2022-12-31¥1.4bn
jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segmentrevenue external2022-07-01 → 2022-12-31¥1.4bn
jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segmentsegment profit2022-07-01 → 2022-12-31−¥18m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentrevenue2022-07-01 → 2022-12-31¥279m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentrevenue external2022-07-01 → 2022-12-31¥277m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentrevenue intersegment2022-07-01 → 2022-12-31¥3m
jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segmentsegment profit2022-07-01 → 2022-12-31¥43m
jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segmentrevenue2022-07-01 → 2022-12-31¥314m
jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segmentrevenue external2022-07-01 → 2022-12-31¥314m
jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segmentsegment profit2022-07-01 → 2022-12-31¥45m
—segment totalrevenue2022-07-01 → 2022-12-31¥4.2bn
—segment totalrevenue external2022-07-01 → 2022-12-31¥4.2bn
—segment totalrevenue intersegment2022-07-01 → 2022-12-31¥3m
—segment totalsegment profit2022-07-01 → 2022-12-31¥500m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 441
ItemContextValueUnit
Other iaPrior1YearInstant46586000JPY
Other iaCurrentQuarterInstant43711000JPY
Intangible assetsPrior1YearInstant46586000JPY
Intangible assetsCurrentQuarterInstant43711000JPY
Investment securitiesPrior1YearInstant20738000JPY
Investment securitiesCurrentQuarterInstant20738000JPY
Other ioaPrior1YearInstant151419000JPY
Other ioaCurrentQuarterInstant115373000JPY
Investments and other assetsPrior1YearInstant172157000JPY
Investments and other assetsCurrentQuarterInstant136112000JPY
Noncurrent assetsPrior1YearInstant270785000JPY
Noncurrent assetsCurrentQuarterInstant231382000JPY
AssetsPrior1YearInstant8239982000JPY
AssetsCurrentQuarterInstant7126071000JPY
Accounts payable tradePrior1YearInstant407707000JPY
Accounts payable tradeCurrentQuarterInstant128460000JPY
Income taxes payablePrior1YearInstant43869000JPY
Income taxes payableCurrentQuarterInstant6475000JPY
Contract liabilitiesPrior1YearInstant307374000JPY
Contract liabilitiesCurrentQuarterInstant296002000JPY
Provision for loss on order received clPrior1YearInstant27207000JPY
Provision for loss on order received clCurrentQuarterInstant22134000JPY
Other clPrior1YearInstant262880000JPY
Other clCurrentQuarterInstant232156000JPY
Current liabilitiesPrior1YearInstant1049039000JPY
Current liabilitiesCurrentQuarterInstant685229000JPY
Net defined benefit liabilityPrior1YearInstant18725000JPY
Net defined benefit liabilityCurrentQuarterInstant17209000JPY
Noncurrent liabilitiesPrior1YearInstant18725000JPY
Noncurrent liabilitiesCurrentQuarterInstant17209000JPY
LiabilitiesPrior1YearInstant1067764000JPY
LiabilitiesCurrentQuarterInstant702438000JPY
Capital stockPrior1YearInstant1836587000JPY
Capital stockCurrentQuarterInstant1836587000JPY
Capital surplusPrior1YearInstant1899955000JPY
Capital surplusCurrentQuarterInstant1956966000JPY
Retained earningsPrior1YearInstant3232312000JPY
Retained earningsCurrentQuarterInstant2613634000JPY
Shareholders equityPrior1YearInstant6968855000JPY
Shareholders equityCurrentQuarterInstant6407188000JPY
Non controlling interestsPrior1YearInstant203362000JPY
Non controlling interestsCurrentQuarterInstant16444000JPY
Net assetsPrior1YearInstant7172217000JPY
Net assetsCurrentQuarterInstant6423632000JPY
Liabilities and net assetsPrior1YearInstant8239982000JPY
Liabilities and net assetsCurrentQuarterInstant7126071000JPY
Net salesPrior1YTDDuration4223839000JPY
Net salesCurrentYTDDuration2840385000JPY
Cost of salesPrior1YTDDuration2200652000JPY
Cost of salesCurrentYTDDuration1461504000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-06-30pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-07-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-07-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-07-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-07-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass